Homologous recombination (HR) DNA repair-deficient (HRD) breast cancers have been shown to be sensitive to DNA repair targeted therapies. Burgeoning evidence suggests that sporadic breast cancers, lacking germline BRCA1/BRCA2 mutations, may also be HRD. We developed a functional ex vivo RAD51-based test to identify HRD primary breast cancers. An integrated approach examining methylation, gene expression, and whole-exome sequencing was employed to ascertain the aetiology of HRD. Functional HRD breast cancers displayed genomic features of lack of competent HR, including large-scale state transitions and specific mutational signatures. Somatic and/or germline genetic alterations resulting in bi-allelic loss-of-function of HR genes underpinned functional HRD in 89% of cases, and were observed in only one of the 15 HR-proficient samples tested. These findings indicate the importance of a comprehensive genetic assessment of bi-allelic alterations in the HR pathway to deliver a precision medicine-based approach to select patients for therapies targeting tumour-specific DNA repair defects.
Introduction
Homologous recombination (HR) plays a critical role in the repair of double strand breaks (DSBs), replication-associated DNA damage, and inter-strand crosslinks [1] . Germline mutations affecting specific known HR repair genes result in an increased risk of breast cancer development [2] . For example, BRCA1 and BRCA2 germline mutations are present in approximately 5-7% of all breast cancers [3] . The protein products encoded by the BRCA1/2 genes are essential members of the HR pathway, assisting in the maintenance of genomic integrity. In the absence of HR, DSBs are repaired by more error-prone mechanisms, such as non-homologous end joining, leading to genomic instability and tumourigenesis. Cells with homologous recombination deficiency (HRD) have been shown to be exquisitely sensitive to platinum-based chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, which produce replication-associated DSBs. Therefore, HRD has been targeted in cancers with the aim of exploiting a tumour-specific deficiency in DNA repair [4] . This 'synthetic lethal' approach has recently led to the approval of PARP inhibitors for BRCA1/2-associated ovarian cancers and the investigation of cisplatin and PARP inhibitors in BRCA1/2-associated breast cancers [5] [6] [7] [8] .
There are burgeoning data suggesting that HRD166 RW Mutter et al Figure 1 . Schematic diagram of the study design. Tumours were prospectively collected from 56 patients for ex vivo functional assessment of the status of the HR pathway, using RAD51 foci analysis. Tumours were classified as HR-deficient or -proficient using this assay. A multi-faceted genomics approach, integrating whole-exome sequencing, analysis of germline mutations, copy number variation, gene expression, and methylation, was then used to determine the underlying aetiology of HRD.
clinic remains challenging. HRD in cancer results in a distinctive pattern of genomic instability, due to the deficiency in error-free DNA DSB repair by HR [10] [11] [12] . Therefore, biomarkers based on genomic landscape 'scars' or 'footprints' [i.e. patterns of somatic genetic alterations assessed by large-scale state transitions (LST), telomeric regions with allelic imbalance (NtAI), or large segments with loss of heterozygosity (Myriad LOH/HRD)], which are commonly seen in BRCA1/2-associated breast cancer due to HRD, have been proposed for the identification of sporadic breast cancers with HRD [13] [14] [15] [16] . Although these genomic landscape biomarkers correlate well with BRCA1/2 germline mutations, their clinical utility in breast cancer has been limited because of their modest positive-predictive value [17, 18] . The DNA recombinase RAD51 forms a focus at DNA damage sites, which become visible using immunofluorescence microscopy, and mark sites of ongoing DNA repair. The recruitment of RAD51 to single-strand DNA catalyses strand invasion and is a crucial step in HR that is dependent on the functional integrity of the entire pathway [1] . Hence, the assessment of RAD51 has been proposed as a surrogate for competent HR DNA repair; however, previous approaches require patients to receive systemic cytotoxic therapy within a short period prior to tumour biopsy for biomarker assessment [19] . To address the unmet need of a test that accurately assesses the functional status of HR at the time of diagnosis, we utilized a functional RAD51 assay to measure HR in prospectively accrued human breast cancer specimens. After benchmarking this assay on the basis of the clinico-pathological and genomics features of the tumours, we sought to define the underlying aetiology of HRD in breast cancers employing a multi-faceted genomic approach ( Figure 1 ) [20] .
Materials and methods

Patients
We obtained fresh and flash frozen tumour specimens from 56 breast cancer patients diagnosed between August 2010 and April 2012 (supplementary material, Table S1 ). This study was approved by the Institutional Review Board, and informed consent was obtained from all patients prior to enrolment. Details of inclusion/exclusion criteria are described in the supplementary materials and methods.
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were then incubated in media for 4 h, after which they were mounted on glass slides. Cell nuclei were analysed for subnuclear foci formation of RAD51 in both the irradiated and the mock-treated (i.e. non-irradiated) states as a functional readout of HR. IR-induced formation of γH2AX foci was analysed to assess the quality of the preparation and cell viability at the time of DNA damage and fixation, in addition to being used as a surrogate for DNA damage. BRCA1 foci formation was also assessed to facilitate the localization of potential defects in the HR pathway. At least 200 nuclei were counted for both the irradiated and the non-irradiated conditions of a given case. A nucleus was scored as positive if it contained more than five foci, as described previously [20] .
Immunohistochemistry (IHC)
IHC analysis was performed on the matching formalin-fixed, paraffin-embedded tissue sections of the breast cancers included in this study using antibodies against PCNA and Ki67 employing standard procedures and validated controls (see supplementary materials and methods).
Nucleic acid extractions
DNA and RNA were extracted from representative flash frozen tumour sections using the DNeasy Blood & Tissue kit (Qiagen, Valencia, CA, USA) and TRIzol (Life Technologies, Grand Island, NY, USA), respectively (see supplementary materials and methods).
BRCA1 promoter methylation
Genomic DNA (100 ng) from each breast cancer was bisulfite-converted using the EpiTect Plus Bisulfite Kit (Qiagen). Purified converted DNA was subjected to methylation-specific PCR (MSPCR) using the EpiTect MSP Kit (Qiagen) as described in the supplementary materials and methods.
Whole-exome sequencing and copy number analysis DNA extracted from snap-frozen tumours and germline were subjected to whole-exome capture using the SureSelect Human All Exon v4 (Agilent, Santa Clara, CA, USA) capture system and to massively parallel sequencing on an Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). Whole-exome sequencing analysis was performed as described in Weinreb et al [21] with modifications (supplementary materials and methods). Prior to analysis, two authors (SNP and NR) curated a list of 95 genes that are direct or indirect effectors or regulators of HR using the literature and author experience [22, 23] . Comparison of the number of cases with the complete loss of both alleles of at least one HR gene according to functional RAD51 foci formation status was performed using Fisher's exact test.
Analysis of genomic 'scars'
Large-scale state transitions (LST), telomeric regions with allelic imbalance (NtAI), or large segments with loss of heterozygosity (Myriad LOH/HRD) scores were derived from whole-exome sequencing data. Derivation of these scores from allele-specific segmented data was determined following methods outlined in the initial publications and described in detail in the supplementary materials and methods [13] [14] [15] .
Analysis of mutational signatures
Mutational signatures were defined using whole-exome sequencing data as described in the supplementary materials and methods.
Data and materials availability
Code used to compute LST, ntAI, HRD/LOH, and perform analysis of mutational signatures is available from the authors upon request. Sequencing data are in the process of being submitted to dbGaP.
Results
Functional analysis of RAD51 foci formation to define HR DNA repair defects HRD was evaluated using quantification of RAD51 foci in cancer cells subjected to ex vivo ionizing radiation (IR), which has previously been shown to be a robust readout of the integrity of HR in vitro [20] . We obtained tumour specimens from 56 consecutive patients with breast cancers prospectively ( Table 1 ). In brief, immediately after surgical resection, we generated single cell suspensions from each tumour. For each patient, half of these suspensions were irradiated with 10 Gy. Cell nuclei were analysed for the formation of RAD51 foci in both irradiated and unirradiated cells. To ascertain that RAD51 deficiency was not due to cellular quiescence, we used immunohistochemical analysis of the proliferation marker Ki67 (supplementary material, Figure  S1A , B). As HR is limited to the S/G2 phases of the cell cycle and an absence of RAD51 induction denotes HRD, we only considered cases for further analysis if they showed sufficient levels of Ki67 staining (proficient > 5%; deficient > 20%; supplementary material, Figure S2 ). Forty-nine tumours had sufficient levels of proliferation, as defined by Ki67, for subsequent analysis. By assessing the induction of RAD51 foci formation in irradiated versus unirradiated cells, we observed that 78% (38/49) of the tumours displayed a significant increase in RAD51 foci following IR (Figure 2A , C), a phenotype that we classified as 'RAD51-proficient'. In addition, 22% (11/49) of the tumours lacked a significant increase in RAD51 foci following IR ( Figure 2B , D). We classified these tumours as 'RAD51-deficient'. The relative fold increase in RAD51 recruitment following IR displayed a clear bimodal distribution in the breast cancers analysed ( Figure 2E ). The 38 RAD51-proficient tumours also displayed BRCA1 foci induction following IR. In seven of the 11 tumours classified as RAD51-deficient, there was also no induction of BRCA1, whereas four RAD51-deficient tumours exhibited a two-to five-fold increase in BRCA1 foci formation following IR. Notwithstanding these four cases, induction of RAD51 foci was linearly related to induction of BRCA1 foci (r = 0.91, p < 0.001; supplementary material, Figure S1C ). RAD51 deficiency (i.e. functional HRD) was observed in all clinical subtypes. A numerically but not statistically significant higher prevalence of functional HRD, however, was documented in triple-negative breast cancers (42%, Figure 2F ). HRD was associated with family history, but no other clinic-pathologic features ( Table 2) .
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Relationship between functional HR assays and genomic 'scars'
We next sought to define whether breast cancers with functional HRD, as defined by the ex vivo RAD51 assay, would display genomic 'scars' or mutational signatures consistent with HRD [13] [14] [15] [16] 24, 25] . A subset of 24 tumours from which sufficient DNA was available, including nine RAD51-defective tumours and 15 RAD51-foci-positive controls (supplementary material, Tables S1 and S2), was subjected to whole-exome sequencing. Consistent with our hypothesis, tumours with functional HRD (i.e. RAD51-deficient) had significantly higher numbers of BRCA1/2-like genomic 'scars' than HR-proficient breast cancers. The LST, ntAI, LOH/HRD scores, and number of insertions and deletions (indels) were significantly higher in tumours with functional HRD (Wilcoxon rank-sum test, p = 0.002, p = 0.009, p = 0.048, and p = 0.044, respectively; Figure 3A -C). The positive predictive value, negative predictive value, and accuracy of LST using a cut-off of 15 (in accordance with the initial report [13] ) to determine RAD51 functional status were 59%, 90%, and 82%, respectively. In addition, using a validated approach to classify cancers into the 21 mutational signatures that shape the genomes of human cancers [24] , we observed that the BRCA1/2 mutational signature (signature 3) was present in four of nine (44%) RAD51-deficient breast cancers but in none of the 15 RAD51-proficient cases (p = 0.02, Fisher's exact test; Figure 5 ), suggesting that this signature may only identify a subset of breast cancers with HRD (i.e. three of five tumours with BRCA1 and BRCA2 pathogenic mutations did not display the BRCA1/2 mutational signature). Taken together, we have demonstrated that HRD breast cancers as defined by a functional RAD51 foci assay display the expected cardinal genomic features of breast cancers lacking competent HR DNA repair (e.g. those of BRCA1/2 hereditary breast cancers).
Integrated genetic analysis of HR-deficient and -proficient tumours
We next sought to identify the aetiology of functional HRD. We measured the mRNA levels of a panel of HR genes, including BRCA1, BRCA2, RAD51, RAP80, and FAM175, in HRD and HR DNA repair competent cases using NanoString technology (Figure 4) . The expression levels of the HR genes were found not to be associated with HRD. Similarly, BRCA1 gene promoter methylation was also not associated with functional HRD status in the tumours analysed, although BRCA1 gene promoter methylation was detected in only two cases.
Given that alterations in multiple HR genes in addition to BRCA1/2 have been associated with either predisposition to breast or ovarian cancer or response to DNA-damaging chemotherapy [2, 26] , we posited that functional HRD may be underpinned by genetic alterations that target distinct components of the HR pathway in sporadic breast cancers. Importantly, there is evidence to suggest that for most HR genes, bi-allelic loss is essential for cancer cells to be HR DNA repair-deficient [9, [27] [28] [29] . Whole-exome sequencing analysis revealed that bi-allelic germline and/or somatic genetic alterations affecting 95 previously reported HR DNA repair pathway genes (supplementary material, Table S3 ) accounted for the functional HRD observed in eight of nine (89%) cases analysed ( Figure 5 and supplementary material, Tables S4-S6) [22, 23] . For instance, four of nine patients with functional HRD harboured alterations in BRCA2 (Figure 5 ), all of which likely resulted in a complete loss of BRCA2 [germline frameshift mutation with LOH (case SP15), somatic frameshift mutation with LOH (case SP28), a somatic exon 3 duplication with LOH (case SP5), and a somatic homozygous deletion (case SP17)]. Consistent with its role upstream of BRCA2 in the HR pathway, IR-induced BRCA1 recruitment into DNA repair foci was preserved in these four tumours. Four additional HRD cases had bi-allelic alterations of bona fide HR genes, including one case with a CHEK2 somatic homozygous deletion (case SP6). Loss of CHEK2 diminishes RAD51 recruitment to the sites of DNA damage following IR (unpublished observation) [30, 31] . The two cases with somatic homozygous deletions of either BRCA2 (case SP17) or CHEK2 (case SP6) had negligible mRNA expression levels of the corresponding gene (supplementary material, Figure  S3 ), providing additional evidence of the functional consequence of the homozygous deletions detected. Two additional HRD cases showed non-synonymous somatic mutations and LOH in FAAP100 (cases SP16 and SP26), a Fanconi anaemia-associated protein.
Integrity of the Fanconi anaemia pathway is required for RAD51 recruitment and HRD results when this pathway is inactivated [32] . Another case had a mutation and LOH in TP53BP1, which may result in a switch from repair of double-strand breaks with fidelity by HR to a reliance on RAD52-mediated mutagenic single-strand annealing [33] . Case SP6, in addition to a CHEK2 homozygous deletion, also harboured a homozygous deletion in BABAM1 (MERIT40 or NBA1), a member of the BRCA1-A complex known to affect BRCA1 and RAD51 recruitment [34] . The only RAD51 foci formation proficient case displaying a bi-allelic inactivation of an HR gene was case SP20. This tumour, despite harbouring a germline frameshift mutation in BRCA1 coupled with LOH of the wild-type allele, was found to be proficient for the induction of RAD51 and BRCA1 foci, and did not display an elevated LST score or a BRCA mutational signature. In addition, this case did not display evidence of intragenic deletions or revertant mutations in the tumour, nor did it have low expression of 53BP1, suggesting that there might be additional mechanisms that can restore HR function in BRCA1-mutant breast cancers [35] [36] [37] .
In total, eight of nine RAD51-deficient cancers harboured a bi-allelic inactivation of at least one HR gene compared with one of 15 RAD51-proficient cancers (p < 0.001, Fisher's exact test), suggesting that these eight cases likely had a genetic aetiology for functional HRD. The sole case that was RAD51-deficient and did not contain bi-allelic inactivation of an HR DNA repair gene also failed to induce BRCA1 foci following IR, and did not have evidence of a genomic scarring (LST) or a mutational signature. Further, BRCA1 promoter methylation was absent and there was not any obvious aberration in the gene expression of BRCA1 or other HR genes. This suggests the possibility that a genetic alteration not surveyed by whole-exome sequencing (e.g. somatic genetic alterations affecting non-protein coding regulatory elements or genetic rearrangements) or an epigenetic alteration may have resulted in HRD in this case. Of note, single-allelic alterations in HR genes occurred in 12 cases and were associated with RAD51 deficiency, albeit less strongly than bi-allelic inactivation (p = 0.01, Fisher's exact test; supplementary material, Figure S4 ). The nine cases with bi-allelic inactivation of HR DNA repair genes, including the BRCA1 germline mutated but RAD51-proficient case, were found to have a significant association with higher LST scores (p = 0.001, Wilcoxon rank-sum test; Figure 3D ). To determine whether the association between bi-allelic inactivation or HR genes and HR deficiency would be generalizable, we performed an analysis of breast cancer samples from The Cancer Genome Atlas (TCGA) study (see supplementary materials and methods) [38] . In the TCGA dataset, breast cancers with a bi-allelic genetic alteration in the HR pathway gene panel also displayed . Wt, wild-type. All comparisons were performed using Wilcoxon rank-sum tests.
significantly higher LST scores than those that did not (p < 0.001, Wilcoxon rank-sum test; supplementary material, Figure S5 ).
Taken together, our findings demonstrate that in eight of nine breast cancers displaying functional HRD, the lack of competent HR DNA repair was likely caused by bi-allelic genetic inactivation of a bona fide HR-related gene. Although we included TP53BP1 in our gene panel of HR regulators and effectors, a priori, we acknowledge that mutations in this gene may promote HR, especially in a BRCA1-mutant background (which was not the case in any of the tumours Figure 5 . Genetic changes in HR genes in RAD51-deficient and -proficient samples. The repertoire of large-scale state transitions (LST), the number of somatic insertions and deletions (indels), and association with BRCA mutational signature, as well as germline and somatic genetic alterations in genes associated with homologous recombination, are presented. Cases are ordered first by RAD51 status, then by increasing LST. The number of indels for each case is divided by size according to the colour key. Cases with a BRCA-associated mutation signature are annotated (see Supplementary materials and methods for details). The grid illustrates the germline and somatic genetic alterations in HR genes. The types of alterations are indicated in the colour key on the right. PIK3CA and TP53 mutation status, receptor, and RAD51 status are annotated in the phenobar (top). Exon duplication refers to a duplication of exon 3 in the BRCA2 gene. ER, oestrogen receptor; TNBC, triple-negative breast cancer.
analysed in this study). Further, emerging evidence suggests that TP53BP1 plays a critical role in supporting the accumulation of RAD51 at IR-induced DNA double-strand breaks. Rather than suppressing HR in a BRCA1 wild-type background, loss of 53BP1 may trigger a hyper-resection phenotype, leading to replacement of RAD51 by RAD52 and redirecting repair from HR to more mutagenic single-strand annealing [33] . Nevertheless, excluding this case (i.e. only seven of nine cases with bona fide bi-allelic HR genes) does not significantly alter our findings. Bi-allelic alterations were still found to be significantly associated with RAD51 deficiency and correlate with LST (p < 0.001 and p < 0.01, Fisher's exact test and Wilcoxon-rank sum test, respectively).
Discussion
Here, we developed and validated an ex vivo functional assay for the identification of HRD breast cancers. This assay revealed that over 20% of the breast cancers analysed were found to have a functional deficiency in the HR pathway. This RAD51 foci-induction assay is the only HRD classifier to display a bimodal distribution, suggesting that there is a biologically driven categorization of breast cancers by status of the HR pathway. Breast cancers classified as functionally HRD displayed the cardinal genomic features reported to be present in tumours lacking competent HR, including high LST scores and the BRCA mutational signature (i.e. signature 3). Although HRD was most frequently observed in 174 RW Mutter et al triple-negative breast cancers, this functional deficiency was also present in ER-positive and/or HER2-positive disease. An integrative genomic analysis of cases with and without HRD revealed that the likeliest aetiology for HRD in the vast majority of cases is bi-allelic inactivation of bona fide HR genes, and that BRCA1 gene promoter methylation and transcriptomic changes in HR genes were not associated with functional HRD. These observations demonstrate that HRD is predominantly caused by genetic events during tumourigenesis and tumour evolution, and that this phenomenon likely constitutes a convergent phenotype in breast cancers [9, 39] .
Germline variants in HR genes besides BRCA1/BRCA2 are associated with breast cancer predisposition, and underlie the importance of assessing the genotype of the entire pathway [2, 40] . Genetic alterations affecting HR pathway-related genes have been linked to response to HR-targeted therapies in multiple other cancers [25, 41, 42] . In ovarian cancer, somatic and germline assessment of a panel of 13 HR genes was significantly associated with platinum sensitivity and overall survival in a cohort of 390 ovarian cancer patients [26] . A phase II trial of a PARP inhibitor in metastatic prostate cancer also identified somatic and/or germline alterations in a panel of DNA repair genes which were significantly associated with response, with 88% of patients who responded to therapy harbouring a genetic alteration in an HR DNA repair-related gene [41] . Our results provide direct evidence to support the novel concept that bi-allelic germline and/or somatic alterations in HR genes, rather than the mere presence of a mutation in these genes, lead to a phenotypic functional defect in HR and provide a mechanistic basis for these recent clinical observations. Further, we extend the significance of a comprehensive somatic and germline genetic assessment of the HR pathway genes to both the risk and the treatment of breast cancer patients.
We were not able to find a clear role for aberrant HR gene expression or BRCA1 promoter methylation in mediating functional HR deficiency in our study. Although methylation of BRCA1 is enriched in breast cancers compared with normal breast epithelium and leads to reduced BRCA1 expression, whether these changes have phenotypic consequences remains unclear [43] . In our cohort of breast cancer patients, we only identified two cases with BRCA1 promoter methylation, of which one case was HR-proficient and the other was HRD. Hence, we did not find clear evidence that would support the contention that epigenetic alterations in BRCA1 deregulate HR. In other malignancies, such as ovarian cancer, BRCA1 promoter methylation occurs in 10-20% of cases and is mutually exclusive of BRCA1 mutation [27] . Interestingly, though, epigenetic dysregulation of HR in ovarian cancer does not appear to be linked with overall survival or progression-free survival after treatment with cisplatin [44] . Ultimately, larger cohorts may be required to link epigenetic changes to phenotypic deficiencies in HR, i.e. drug response, in vitro assays, or genomic scars.
The only patient with dysfunctional HR who did not have a bi-allelic alteration in a bona fide HR gene also lacked evidence of a genomic 'scar' or mutational signature consistent with HRD. On the opposite end of the spectrum, we identified one tumour with a bi-allelic BRCA1 mutation without evidence of a functional deficit in HR. This case did not display evidence of intragenic deletions or reversion mutations in the tumour. Moreover, 53BP1 gene expression was assessed, and levels were not significantly lower than those detected in other samples. Other mechanisms of restoring DNA repair in BRCA1-deficient tumour cells have been reported, such as alterations in RIF1, HELB, PTIP or MAD2L2 [45] [46] [47] [48] . In addition, this case displayed a frameshift mutation in BRCA1 at the C-terminus in the second BRCT domain (Gln1777fs) and also lacked both a high LST score and mutational signature 3. In ovarian cancer, mutations towards the end of the gene have been associated with a worse overall survival (as opposed to mutation in other portions of the gene which are associated with improved survival) -suggesting the possibility that this particular mutation may not necessarily result in an HR deficiency [49] .
Consistent with the notion that genomic 'scars' and mutational signatures are present in breast cancers with HRD, here we demonstrated using a functional HRD test that these genomic 'scars' and mutational signatures are present not only in BRCA1/BRCA2 breast cancers but also in non-BRCA1/BRCA2 breast cancers displaying functional HRD. It should be noted, however, that the mutational signature of BRCA1 and/or BRCA2 breast cancers (signature 3 from Alexandrov et al [24] ) seems to identify a more limited subset of HRD breast cancers than the ex vivo RAD51-based functional assessment described here. In addition, genomic 'scar' predictors of HRD only have moderate positive predictive value for functional HRD, providing one reason for the modest utility of these assays in clinical trials [17, 18] . Using the finding from our clinical data of a strong relationship between functional HRD and bi-allelic alterations in HR genes, we interrogated the TCGA data to identify cases with bi-allelic alterations in DNA repair genes. As anticipated, TCGA cases with bi-allelic alterations had a higher prevalence of genomic scars (i.e. high LST score), providing additional support for our hypothesis.
The results of the functional RAD51 assay described here, in conjunction with other studies [19, 50] , highlight the need for a biomarker of HR function to select breast cancer patients who may benefit from synthetic lethal approaches targeting HRD. Direct testing of induced RAD51 is challenging to implement as a routine clinical test, due to the need for fresh tissue, rapid processing, and specialized assessment [51] . In a translational setting, however, functional assessment of the HR pathway can allow for a more thorough interpretation of genomic alterations measured simultaneously. Bi-allelic inactivation of HR genes was found to identify almost 90% of cases with a functional HR defect, with only one false-positive result.
This study has important limitations, including the relatively small sample size. Moreover, functional ex vivo testing is difficult to perform in a large-scale setting. We used research versions of LST and other genomic 'scar' methods, which may slightly alter the performance characteristics described here. Lastly, one of the genes in our a priori determined panel of HR genes, TP53BP1, is known to regulate pathway choice between HR and NHEJ [52] . In a BRCA1-mutant background, depletion of TP53BP1 rescues an HR defective phenotype. Recent work, however, has suggested that in a BRCA1 wild-type setting, TP53BP1 is important for adequate RAD51 induction after IR and that exhaustion of TP53BP1 leads to hyper-resection (and possibly faulty HR) [33] . Regardless, the exclusion of this particular case (SP29) does not significantly alter our observation that bi-allelic inactivation of HR DNA repair-related genes is significantly associated with functional HRD and high LST scores.
In conclusion, we identified the genetic basis of HR deficiency in breast cancer by correlating a functional phenotype with bi-allelic genotypic alterations in HR genes. Our results indicate that HR panel gene sequencing would succeed in predicting HR function with almost 90% accuracy. Lastly, our work highlights the importance of having bi-allelic alterations in the HR pathway, as opposed to 'single hits', to result in a functional deficiency in HR. Comprehensive sequencing of HR genes may allow for a precision medicine approach for DNA-damaging therapies and warrants further investigation in large cohorts from prospective clinical trials. Figure S1 . Relationship between RAD51 induction and proliferation and BRCA1 induction Table S1 . Clinical features of breast cancer patients whose tumours were subjected to whole-exome sequencing 
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